2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
November 2024 in “Medicina” Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
15 citations
,
June 2020 in “Processes” CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
4 citations
,
January 2025 in “Dermatologica Sinica” Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
February 2026 in “Journal of Allergy and Clinical Immunology” Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.